The demo attained both equally its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and exceptional enhancements in liver fibrosis with no worsening of steatohepatitis, together with resolution of steatohepatitis without any worsening of liver fibrosis in individuals with MASH when compared to placebo.1Assuming the